FDA Clearance Tracker · P160046
VENTANA PD-L1 (SP263) ASSAY
Last checked: Nov 20, 2026Latest source record: May 1, 2017 (this decision)Source: openFDAMethods & limitations
Decided
May 1, 2017
Approved
Time to decision
193 days
Received Oct 20, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160046
- Device name
- VENTANA PD-L1 (SP263) ASSAY
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Oct 20, 2016
- Decided
- May 1, 2017
- Decision
- Approved
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the VENTANA PD-L1 (SP263) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma tissue stained with OptiView DAB IHC Detection Kit on a VENTANA BenchMark ULTRA instrument.PD-L1 status is determined by the percentage of tumor cells with any membrane staining above background or by the percentage of tumor-associated immune cells with staining (IC+) at any intensity above background. The percent of tumor area occupied by any tumor-associated immune cells (Immune Cells Present, ICP) is used to determine IC+, which is the percent area of ICP exhibiting PD-L1 positive immune cell staining. PD-L1 status is considered High if any of the following are met:1) >= 25% of tumor cells exhibit membrane staining; or,2) ICP > 1% and IC+ ? 25%; or,3) ICP = 1% and IC+ = 100%.PD-L1 High status as determined by VENTANA PD-L1 (SP263) Assay was associated with increased objective response rate (ORR) in a single arm study of IMFINZI (durvalumab).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PLS. The earliest in FDA's data is P150013, decided Oct 2, 2015.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.